Lee D-G, Chae H, Yim Dong-Seok, Park S H, Choi S-M, Kim S, Choi J-H, Yoo J-H, Shin W-S
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul, Korea.
J Clin Pharm Ther. 2009 Jun;34(3):337-44. doi: 10.1111/j.1365-2710.2008.00999.x.
Empirical use of intravenous (IV) itraconazole (ITZ) for febrile neutropenic patients has recently been introduced in Korea. This study was designed to investigate the population pharmacokinetics (PK) of IV-ITZ.
Sparse PK data were collected from febrile neutropenic patients undergoing empirical ITZ therapy at 200 mg/day after loading doses. NONMEM (Version. 5.1.1) was used to estimate population PK parameters.
Forty-two patients were enrolled in the study. Mean population CL and V of IV-ITZ were 10 L/h and 1050 L, respectively. Body weight was the only contributing covariate of CL. The median simulated trough concentration of ITZ after 10 days was predicted to be about 700 ng/mL.
In this study, we explored the population PK profile of ITZ given in IV formulation. We found that the current dosage regimen of IV-ITZ (200 mg/day) was appropriate to obtain therapeutic trough concentrations for neutropenic patients in Korea.
韩国最近开始对发热性中性粒细胞减少症患者经验性使用静脉注射（IV）伊曲康唑（ITZ）。本研究旨在调查静脉注射伊曲康唑的群体药代动力学（PK）。
从接受经验性ITZ治疗、负荷剂量后每日200mg的发热性中性粒细胞减少症患者中收集稀疏的PK数据。使用NONMEM（版本5.1.1）估算群体PK参数。
42例患者纳入本研究。静脉注射伊曲康唑的平均群体清除率（CL）和分布容积（V）分别为10L/h和1050L。体重是CL的唯一影响协变量。预计10天后伊曲康唑的模拟谷浓度中位数约为700ng/mL。
在本研究中，我们探讨了静脉注射剂型伊曲康唑的群体PK特征。我们发现，目前静脉注射伊曲康唑的给药方案（每日200mg）适合在韩国为中性粒细胞减少症患者获得治疗性谷浓度。
